Marshall Wace’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-212,581
| Closed | -$15.3M | – | 3616 |
|
|
2025
Q4 | $15.3M | Sell |
212,581
-427,003
| -67% | -$27.6M | 0.01% | 726 |
|
|
2025
Q3 | $27.9M | Buy |
639,584
+579,361
| +962% | +$23.4M | 0.03% | 519 |
|
|
2025
Q2 | $1.71M | Sell |
60,223
-394,972
| -87% | -$11.8M | ﹤0.01% | 1634 |
|
|
2025
Q1 | $13.4M | Buy |
455,195
+292,332
| +179% | +$9.1M | 0.02% | 662 |
|
|
2024
Q4 | $4.74M | Sell |
162,863
-19,342
| -11% | -$808K | 0.01% | 1091 |
|
|
2024
Q3 | $8.37M | Buy |
182,205
+70,435
| +63% | +$3.06M | 0.01% | 822 |
|
|
2024
Q2 | $4.57M | Buy |
111,770
+9,906
| +10% | +$284K | 0.01% | 1033 |
|
|
2024
Q1 | $2.6M | Sell |
101,864
-95,852
| -48% | -$1.5M | ﹤0.01% | 1243 |
|
|
2023
Q4 | $1.79M | Buy |
+197,716
| New | +$1.32M | ﹤0.01% | 1267 |
|
|
2022
Q3 | – | Sell |
-264,588
| Closed | -$3.85M | – | 3724 |
|
|
2022
Q2 | $3.85M | Hold |
264,588
| – | – | 0.01% | 1547 |
|
|
2022
Q1 | $4.89M | Hold |
264,588
| – | – | 0.01% | 1387 |
|
|
2021
Q4 | $6.29M | Buy |
264,588
+249,755
| +1,684% | +$5.96M | 0.01% | 1187 |
|
|
2021
Q3 | $365K | Hold |
14,833
| – | – | ﹤0.01% | 2556 |
|
|
2021
Q2 | $367K | Buy |
+14,833
| New | +$345K | ﹤0.01% | 2258 |
|
Other funds holding RNAM
Marshall Wace's RNAM Position: Q1 2026 in Review
Marshall Wace sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 212,581 shares — an estimated $15.3M sold.
Marshall Wace first reported a position in RNAM in Q2 2021 and held it in 14 quarters. The position peaked at $27.9M in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Marshall Wace reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Marshall Wace sold 212,581 Avidity Biosciences shares in Q1 2026, an estimated $15.3M.
- Marshall Wace first reported a position in Avidity Biosciences in Q2 2021 and held it in 14 quarters.
- Marshall Wace's Avidity Biosciences position peaked at $27.9M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.